Market Overview

UPDATE: Cantor Fitzgerald Initiates Coverage on Myriad Genetics on Position in Molecular Diagnostic Franchises

Share:
Related MYGN
Barclays Explains Its Bullish Call On Myriad Genetics
Myriad Gets $200 Million More For Share Repurchase Program

In a report published on Friday, analysts at Cantor Fitzgerald initiated coverage on Myriad Genetics (NASDAQ: MYGN) with a Buy rating and $40 PT.

In the report, lead analyst Sung Ji Nam commented that, "We are initiating coverage of MYGN with a BUY rating and $40 PT. With its current flagship product BRACAnalysis, MYGN has built one of the most successful, high-value molecular diagnostic franchises (~$500mm business), and we believe the company is well-positioned to execute industry-leading growth (top and bottom lines) over the next several years, driven by its competitive product portfolio and pipeline, as well as unmatched capabilities in diagnostic research, market development and commercialization capabilities."

Myriad Genetics closed on Thursday at $31.06

Latest Ratings for MYGN

DateFirmActionFromTo
May 2016Avondale PartnersMaintainsMarket Outperform
May 2016Leerink SwannMaintainsMarket Perform
Jan 2016Deutsche BankInitiates Coverage onBuy

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: Cantor Fitzgerald Sung Ji NamAnalyst Color Initiation Analyst Ratings

 

Related Articles (MYGN)

View Comments and Join the Discussion!